Home » Pfizer and BioNTech Report Positive Results from COVID-19 Vaccine Trial
Pfizer and BioNTech Report Positive Results from COVID-19 Vaccine Trial
Pfizer and BioNTech have announced positive early results from a phase 1 /2 study of their lead COVID-19 vaccine candidate in the U.S.
All 24 volunteers who received either two 10 mcg or 30 mcg doses of the messenger RNA-based vaccine produced neutralizing antibodies up to 2.8 times more than those seen in recovered COVID-19 patients, and no serious adverse events were reported.
The companies expect to begin a phase 2b/3 trial of the vaccine later this month.
Upcoming Events
-
21Mar
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr